Shareholders approve issuance of up to 6.4M warrant shares; name change rejected

Moleculin Biotech, Inc.

Shareholders approved issuance of up to 6,367,956 shares upon exercise of warrants issued Feb 20, 2026.
Name change to Moleculin Inc. failed; received 2,015,174 'For' votes but needed majority of 4,933,110 outstanding shares.
Adjournment proposal passed to allow further proxy solicitation if needed.
A total of 2,382,989 shares were present at the Special Meeting, constituting a quorum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.